Strongyloidiasis—a poorly understood parasitic worm disease common in remote Australian communities and some returned travelers, refugees or asylum seekers—is finally gaining attention in the national research arena.
Jan 12, 2024
0
0
Drug-resistant babesiosis may respond to a novel combination therapy, researchers say. The treatment, which involves the antimalarial drug tafenoquine and the anti-fungal/anti-parasite drug atovaquone, may also provide immunity ...
Jan 8, 2024
0
0
For the first time in 20 years, locally transmitted cases of malaria have been reported in the U.S.
Dec 20, 2023
0
0
The world's first medicine formulated to treat a damaging tropical parasite infection in preschool children received the green light Friday from Europe's drug agency.
Dec 15, 2023
0
0
Researchers at The Park Center for Mental Health, Australia, have added to the growing body of evidence that cat ownership is a major risk factor for schizophrenia and quantified the risk at more than double.
Researchers who have studied malaria for decades, hoping to find a cure, long thought they'd identified a type of blood that seemed to defend against the disease.
Dec 6, 2023
0
12
COVID-19 cast a glaring spotlight on the devastating impact that infectious diseases can have on human health and society. At the height of the global pandemic, most of the world came to a standstill, and millions of lives ...
Dec 5, 2023
0
0
For the first time, scientists have begun to figure out why the disfiguring skin lesions caused by cutaneous leishmaniasis don't hurt.
Nov 30, 2023
0
35
Similar to a burglar breaking a window to get into a house, Indiana University researchers have discovered a previously unknown process by which pathogens enter a cell with physical force, breaching the body's immune defenses ...
Nov 30, 2023
0
44
Epilepsy, also known as seizure disorder, is common, and there are many types. About one in 26 people in the U.S. will develop the disease in their lifetime. It affects people of all races, ethnic backgrounds and ages. Anyone ...
Nov 30, 2023
0
2
